Unmet Needs in the Management of Patients with Low-risk MDS

Despite advances in therapy, significant unmet needs remain in the management of patients with low-risk MDS. Many patients continue to experience symptomatic anemia, transfusion dependence, and fatigue, which can substantially impact quality of life. Additionally, there is a need for more predictive biomarkers to guide therapy selection, identify ESA nonresponders earlier, and optimize the timing of interventions. Long-term safety data and head-to-head comparisons of novel agents are limited, making it challenging to determine the most effective sequencing strategies. Improved supportive care approaches, strategies to minimize iron overload, and interventions targeting functional outcomes and patient-reported quality of life remain key areas for future research and development in low-risk MDS management.